Oncology Development Articles & Analysis
13 articles found
Alfa Cytology has revealed new FAP-targeted therapeutics development services that aim to develop precise and effective cancer treatments. ...
Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development services for cancer. ...
Alfa Cytology introduces comprehensive small molecule PARPi development services for combating various diseases. Alfa Cytology, a developer of oncology innovation, has announced its latest venture small molecule Poly(ADP-ribose) polymerase inhibitor development services. ...
The battle against brain tumors is being revolutionized by biotechnology, leveraging cutting-edge innovations to develop more effective treatments. Overall, the integration of multi-omics data and advancements in immune-oncology plays a significant part in developing precise treatments for brain tumors2. ...
Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for precision medicine. ...
ByTempus
Oncology drug development makes up almost half of the annual R&D expenditure of biopharmaceutical companies. ...
Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. ...
Ongoing research and inventions in the field of oncology focus on the development of small molecule drug therapies for use in brain tumor resection. Small molecule drugs are being developed to target and effectively treat brain tumors to improve therapeutic outcomes. ...
TPD drugs are one of the hot spots of new drug development in recent years, especially in the field of oncology. For example, a TPD drug developed by Arvinas has achieved proof-of-concept in clinical trials for the treatment of breast and prostate cancer. ...
Snyder to Navigating Cancer’s Board and especially value her point of view as a recognized leader in oncology and therapeutic development,” said Bill Bunker, Navigating Cancer’s CEO. ...
According to the WHO, infections with HSV-1 and HSV-2 are common in patients infected with HIV. Patients may develop herpetic lesions at multiple sites, including the lips and oropharynx, genitalia, anus, fingers, and skin. ...
Introducing Beacon Biosignals: a neurotechnology company founded to develop machine learning-enabled EEG neurobiomarkers and accelerate precision medicine for any disease state affecting the brain Founded by MD/PhDs and engineers from Harvard and MIT, Beacon is propelled by the vision of a computing platform designed to scale the interrogation of large brain datasets with ...
It provides access to a comprehensive collection of well-established tumor models for early-stage oncology research and increases their translational capabilities to the clinic. ...